Study wrapper · #323
Female Sexual Desire, Arousal, and Orgasmic Dysfunctions: A Systematic Review and Meta-Analysis of Treatment Options.
Editor's note
This is a systematic review and meta-analysis — near the top of the evidence hierarchy — and one of the stronger pieces of context for bremelanotide in this set. From nearly 9,000 screened abstracts, 36 studies (26 RCTs) met criteria, and the authors pooled data for mindfulness-based CBT, flibanserin, and bremelanotide in women with desire, arousal, or orgasm dysfunction without sexual pain. For bremelanotide, they report statistically significant improvement in total Female Sexual Function Index scores and its desire and arousal subscales, plus reduced distress. Two caveats temper this. First, no study directly compared the peptide against psychotherapy, so relative benefit is unknown. Second, the meta-analysis inherits the modest effect sizes and heterogeneous, self-report endpoints of the underlying trials, which other authors have criticized. The finding is consistent with bremelanotide's approved profile: a real but modest, distress-reducing effect in a specific population, not a large or broadly generalizable one.
Plain-language abstract
This is a systematic review and meta-analysis — a study that pools results from many earlier trials — looking at treatments for women with low sexual desire, arousal, or orgasm difficulties, excluding women whose main problem was pain during sex. The authors searched six databases, screened about 8,994 study summaries, and ultimately combined data from 36 studies, most of which were randomized controlled trials. They were able to statistically pool results for three approaches: mindfulness-based cognitive behavioral therapy (a talking therapy), and the medications flibanserin and bremelanotide. Mindfulness-based therapy improved overall sexual function and the desire, arousal, and orgasm components. Flibanserin mainly improved desire. Bremelanotide improved overall sexual function and both the desire and arousal components. All three also lowered sexual distress. Importantly, no study directly compared talking therapy against medication, so the authors could not say which works better. They also note that differing definitions and outcome measures across studies limited firmer conclusions. The takeaway is that several options showed measurable benefit, with bremelanotide's benefit centered on desire and arousal.